Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer
出版年份 2018 全文链接
标题
Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer
作者
关键词
-
出版物
Cancers
Volume 11, Issue 1, Pages 30
出版商
MDPI AG
发表日期
2018-12-29
DOI
10.3390/cancers11010030
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO MetabolitesNovelty and Significance
- (2018) Anne Robdrup Tinning et al. HYPERTENSION
- Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events
- (2018) Rhian M. Touyz et al. Journal of the American Society of Hypertension
- Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition
- (2017) Rhian M. Touyz et al. HYPERTENSION
- Medical treatment of renal cancer: new horizons
- (2016) Basma Greef et al. BRITISH JOURNAL OF CANCER
- Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients
- (2016) Bo Liu et al. Oncotarget
- Etiology of angiogenesis inhibition-related hypertension
- (2015) Stephanie Lankhorst et al. CURRENT OPINION IN PHARMACOLOGY
- Large artery stiffness and hypertension after antiangiogenic drugs
- (2015) Maureen Alivon et al. JOURNAL OF HYPERTENSION
- Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway
- (2014) Ole-Petter R. Hamnvik et al. CANCER
- Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress
- (2013) Stephanie Lankhorst et al. ANTIOXIDANTS & REDOX SIGNALING
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension
- (2012) Peter Kruzliak et al. ANGIOGENESIS
- Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension
- (2012) K Eechoute et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents
- (2012) P. Larochelle et al. Current Oncology
- Nitric oxide and adverse events of vascular endothelial growth factor inhibitors
- (2011) Jecko Thachil CURRENT MEDICAL RESEARCH AND OPINION
- The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System
- (2011) Mariëtte H.W. Kappers et al. HYPERTENSION
- Proteinuria and hypertension with tyrosine kinase inhibitors
- (2011) Praveen Kandula et al. KIDNEY INTERNATIONAL
- Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review
- (2011) D. Keefe et al. ONCOLOGIST
- Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency
- (2010) G. Khan et al. ANNALS OF ONCOLOGY
- Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon
- (2010) M. P. de Boer et al. ANNALS OF ONCOLOGY
- Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels
- (2010) Mariëtte H.W. Kappers et al. HYPERTENSION
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
- (2009) Carie S. Facemire et al. HYPERTENSION
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
- (2008) N. Steeghs et al. CLINICAL CANCER RESEARCH
- Home Blood-Pressure Monitoring in Patients Receiving Sunitinib
- (2008) Michel Azizi et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started